<DOC>
	<DOCNO>NCT01915602</DOCNO>
	<brief_summary>This study investigate potential clinical benefit refametinib give combination sorafenib first line treatment patient unresectable metastatic HCC carry RAS mutation . The study conduct 2 stage . Approximately 95 patient ( 15 Stage 1/ 80 Stage 2 ) accrue study receive treatment . Stage 2 trial conduct least 5 15 patient Stage 1 show least partial response accord objective criterion evaluate tumor size base contrast enhancement [ modify response evaluation criterion solid tumor ( mRECIST ) ] assess external independent radiologist . Refametenib oral ( i.e . take mouth ) protein kinase inhibitor . A kinase inhibitor target certain key protein essential survival cancer cell . By specifically target protein , refametinib combination sorafenib may stop cancer growth . The growth tumor may decrease prevent specific protein function . The primary endpoint ( meaningful result track ) study base rate response , i.e . disease get small . The aim show therapy refametinib combination sorafenib improves response rate patient population compare historical result observe sorafenib .</brief_summary>
	<brief_title>Refametinib Combination With Sorafenib RAS Mutant Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Eligibility criterion RAS mutation test Unresectable metastatic HCC , confirm either histology clinically accord American Association Study Liver Disease ( AASLD ) criterion cirrhotic patient . For noncirrhotic patient , histological confirmation mandatory . Male female ≥18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance state 0 1 . Life expectancy least 12 week . No prior use target agent , experimental therapy systemic anticancer treatment . No previous treatment sorafenib refametinib . Criteria study treatment eligibility Patient must harbor GTPase Kirsten rat sarcoma viral oncogene homolog ( KRAS ) Neuroblastoma RAS viral oncogene homolog ( NRAS ) mutation base Beads , emulsion , amplification , magnetic technology , sensitive mutation detection ( BEAMing ) plasma test . Patients must least one unidimensional measurable lesion Computed tomography ( CT ) Magnetic resonance ( MR ) accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Modified Response Evaluation Criteria Solid Tumors ( mRECIST ) either naïve ( previously treat local therapy surgery , radiation therapy , hepatic arterial therapy , chemoembolization , radiofrequency ablation , percutaneous ethanol injection cryoablation ) previously treat progressed baseline ( measureable lesion and/or progress lesion confirm central image review baseline progression scan ) . ECOG performance status 0 1 . Liver function status ChildPugh Class A . Adequate bone morrow , liver , renal function Patient within normal range cardiac function confirm enrol clinical institute measure echocardiogram multiple gate acquisition ( MUGA ) scan . Patients therapeutically anticoagulated agent warfarin heparin allow participate provide prior evidence underlie abnormality parameter exist . Close monitoring least weekly evaluation perform International normalized ratio ( INR ) stable ( within Child Pugh class A threshold ) base measurement predose , define local standard care . Any Cancer curatively treat &lt; 3 year prior study entry , except cervical carcinoma situ ( CIS ) , treat basal cell carcinoma , superficial bladder tumor [ Staging : noninvasive papillary tumor ( Ta ) , CIS carcinoma ( Tis ) tumor invades lamina propria ( T1 ) ] . Patients eligible surgery , liver transplantation , ablation transarterial chemoembolization HCC . History cardiac disease : Congestive heart failure New York Heart Association ( NYHA ) &gt; class 2 . Unstable angina ( angina symptom rest , newonset angina i.e . within last 3 month ) myocardial infarction ( MI ) within past 6 month prior start screen . Cardiac arrhythmia require antiarrhythmic therapy . QTc ( correct QT interval ) &gt; 480 m Uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg despite optimal medical management ) . Ongoing infection &gt; Grade 2 accord National Cancer Institute Common Toxicity Criteria Adverse Events version 4.03 ( NCICTCAE version 4.03 ) Hepatitis B allow active replication ( define abnormal Alanine aminotransferase [ ALT ] &gt; 2x Upper limit normal [ ULN ] associate Hepatitis B virus [ HBV ] DNA &gt; 20,000 IU/mL ) present . Hepatitis C allow antiviral treatment require . Known history , symptomatic metastatic brain meningeal tumor ( head CT MR Screening confirm absence central nervous system [ CNS ] disease patient symptom suggestive consistent CNS disease ) . History interstitial lung disease ( ILD ) . History hepatic encephalopathy . History organ allograft , cornea transplantation allow . History current evidence retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) . Visible retinal pathology assess ophthalmologic exam consider risk factor RVO CSR .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Mitogen-activated Extracellular-signal-regulated kinase ( MEK ) inhibitor</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Objective tumor response rate ( ORR )</keyword>
	<keyword>modify RECIST criterion</keyword>
</DOC>